{"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 , 9.3 )] Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions ( 5.2 )] Increased Blood Pressure and Heart Rate [see Warnings and Precautions ( 5.3 )] Psychiatric Adverse Reactions [see Warnings and Precautions ( 5.4 )] Priapism [see Warnings and Precautions ( 5.5 )] Peripheral Vasculopathy, including Raynaud’s Phenomenon [see Warnings and Precautions ( 5.6 )] Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions ( 5.7 )] Acute Angle Closure Glaucoma [see Warnings and Precautions ( 5.8 )] Increased Intraocular Pressure and Glaucoma [see Warnings and Precautions ( 5.9 )] Motor and Verbal Tics, and Worsening of Tourette Syndrome [see Warnings and Precautions ( 5.10 )] The most common adverse reactions (≥ 5% in METADATE-CD-treated patients and greater than in placebo-treated patients) were headache, anorexia, abdominal pain, and insomnia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety database is based on three clinical studies of Methylphenidate HCl Extended-Release Capsules CD (i.e., Studies 1, 2, and 3) that included 188 Methylphenidate HCl Extended-Release Capsules CD-treated pediatric patients 6 years of age and older with ADHD. Pediatric patients received Methylphenidate HCl Extended-Release Capsules CD 20 mg, 40 mg, and/or 60 mg once daily: Study 1 was a 3-week placebo-controlled clinical study that included 314 pediatric patients (ages 6 to 15 years; Methylphenidate HCl Extended-Release Capsules CD n=155) Study 2 was a placebo-controlled, crossover clinical study that included 25 pediatric patients (ages 7 to 12 years); and Study 3 was an uncontrolled clinical study that included 8 pediatric patients (ages 6 to 10 years). Adverse Reactions Leading to Discontinuation of Treatment In Study 1, 1% (2/155) Methylphenidate HCl Extended-Release Capsules CD-treated patients and no placebo-treated patients discontinued due to an adverse reaction. One Methylphenidate HCl Extended-Release Capsules CD-treated patient discontinued due to rash and pruritus; and the other Methylphenidate HCl Extended-Release Capsules CD-treated patient discontinued due headache, abdominal pain, and dizziness. Most Common Adverse Reactions The most common adverse reactions that occurred in 5% or more of Methylphenidate HCl Extended-Release Capsules CD-treated and at least twice as great in the Methylphenidate HCl Extended-Release Capsules CD-treated patients compared to the placebo-treated patients in a pool of Studies 1, 2 and 3 in pediatric patients 6 to 15 years of age were anorexia and insomnia. Adverse reactions that occurred in ≥5% of Methylphenidate HCl Extended-Release Capsules CD-treated patients with a greater incidence in Methylphenidate HCl Extended-Release Capsules CD-treated patients than placebo-treated patients in pooled Studies, 1, 2, and 3 are presented in Table 2: Table 2: Adverse Reactions 1 in Pediatric Patients Ages 6 to 15 Years with ADHD in Pooled Three to Four Week Trials (Studies 1, 2, and 3) Methylphenidate HCl Extended-Release Capsules CD (n=188) Placebo (n=190) Headache 12% 8% Anorexia 9% 2% Abdominal Pain 7% 4% Insomnia 5% 2% 1 Adverse reactions that occurred in ≥5% of Methylphenidate HCl Extended-Release Capsules CD-treated patients with a greater incidence in Methylphenidate HCl Extended-Release Capsules CD-treated patients than placebo-treated patients 6.2 Postmarketing Experience The following adverse reactions have been identified during postmarketing use of Methylphenidate HCl Extended-Release Capsules CD and other methylphenidate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse Reactions with Methylphenidate HCl Extended-Release Capsules CD Blood and the lymphatic system disorders: thrombocytopenia Cardiac disorders: cardiac arrest, sudden death Immune system disorders: angioedema Musculoskeletal and connective tissue disorders: rhabdomyolysis Psychiatric disorders: abnormal behavior, aggression, anxiety, irritability, obsessive-compulsive disorder, suicidal behavior (including completed suicide), libido changes, serotonin syndrome in combination with serotonergic drugs Nervous System Disorder: migraine, reversible ischemic neurological deficit, bruxism Skin and subcutaneous tissue disorders: fixed drug eruption Vascular disorders: peripheral coldness, Raynaud’s phenomenon Adverse Reactions with Other Methylphenidate Products Blood and the lymphatic system disorders: leukopenia, anemia, pancytopenia Cardiac disorders: palpitations; increased blood pressure, tachycardia, angina pectoris, cardiac arrhythmia, myocardial infarction, bradycardia, extrasystole Eye disorders: blurred vision, difficulties in visual accommodation, diplopia, increased intraocular pressure, mydriasis Gastrointestinal disorders: nausea, abdominal pain, dry mouth, vomiting, dyspepsia, diarrhea, constipation General Disorders: fatigue, hyperpyrexia Hepatobiliary disorders: abnormal liver function, ranging from transaminase elevation to severe hepatic injury Immune system disorders: hypersensitivity, including anaphylaxis, auricular swelling, bullous conditions, eruptions, exanthemas Infections and infestations: nasopharyngitis Metabolism and nutrition disorders: decreased appetite, reduced weight gain and suppression of growth during prolonged use in pediatric patients Musculoskeletal and connective tissue disorders: arthralgia, muscle cramps, myalgia, muscle twitching Nervous System Disorder: nervousness, dizziness, headache, dyskinesia, including choreoatheetoid movements, drowsiness, tremor, convulsions, cerebrovascular disorders (including vasculitis, cerebral hemorrhages and cerebrovascular accidents), serotonin syndrome in combination with serotonergic drugs, motor and verbal tics Psychiatric disorders: depressed mood, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), affect liability, mania, disorientation Renal and urinary disorders: hematuria Reproductive system and breast disorders: gynecomastia Respiratory, thoracic and mediastinal disorders: pharyngolaryngeal pain, dyspnea, cough Skin and subcutaneous tissue disorders: scalp hair loss, hyperhidrosis, angioneurotic edema, erythema, exfoliative dermatitis, thrombocytopenic purpura, urticaria, erythema multiforme rash Urogenital disorders: priapism Vascular disorders: isolated cases of cerebral arteritis and/or occlusion"],"adverse_reactions_table":["<table> <col/> <col/> <col/> <tbody> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Methylphenidate HCl </content> </paragraph> <paragraph> <content styleCode=\"bold\">Extended-Release </content> </paragraph> <paragraph> <content styleCode=\"bold\">Capsules CD</content> </paragraph> <content styleCode=\"bold\"> (n=188)</content> </td> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Placebo</content>   <content styleCode=\"bold\"> (n=190)</content> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Headache </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 12%</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 8%</td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> Anorexia</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 9%</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 2%</td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> Abdominal Pain</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 7%</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 4%</td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> Insomnia</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 5%</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> 2%</td> </tr> </tbody> </table>"],"boxed_warning":["WARNING: ABUSE, MISUSE, AND ADDICTION Methylphenidate HCl Extended-Release Capsules CD has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing Methylphenidate HCl Extended-Release Capsules CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of Methylphenidate HCl Extended-Release Capsules CD, and proper disposal of any unused drug. Throughout Methylphenidate HCl Extended-Release Capsules CD treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning. Methylphenidate HCl Extended-Release Capsules CD has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can result in overdose and death ( 5.1 , 9.2 , 10 ): Before prescribing Methylphenidate HCl Extended-Release Capsules CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of Methylphenidate HCl Extended-Release Capsules CD, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dosage of approximately 60 mg/kg per day. This dosage is approximately 2 times the maximum recommended human dosage (MRHD) of 60 mg/day given to children on a mg/m 2 basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown. Methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dosage used was approximately 45 mg/kg/day, which is approximately 4 times the MRHD (children) on a mg/m 2 basis. In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dosage groups were exposed to 60 to 74 mg/kg per day of methylphenidate. Mutagenesis Methylphenidate was not mutagenic in the in vitro Ames reverse mutation assay, in the in vitro mouse lymphoma cell forward mutation assay, or in the in vitro chromosomal aberration assay using human lymphocytes. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary cells. Methylphenidate was negative in vivo in males and females in the mouse bone marrow micronucleus assay. Impairment of Fertility Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at dosages up to 160 mg/kg per day, approximately 10 times the maximum recommended human dosage of 60 mg/day given to adolescents on a mg/m 2 basis."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action of Methylphenidate HCl Extended-Release Capsules CD in the treatment of ADHD in pediatric patients 6 years of age and older is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space. 12.2 Pharmacodynamics Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD have not been fully characterized. 12.3 Pharmacokinetics Following one week of 20 mg/day or 40 mg/day of Methylphenidate HCl Extended-Release Capsules CD to pediatric patients aged 7 to12 years old with ADHD, C max and AUC of methylphenidate were approximately proportional to the administered dosage. Absorption Following administration of Methylphenidate HCl Extended-Release Capsules CD in pediatric patients aged 7 to 12 years old with ADHD, the plasma concentration time profile of methylphenidate showed two phases of drug release with a sharp, initial slope similar to a methylphenidate immediate-release tablet (median T max1 about 1.5 hours post dosage), and a second rising portion approximately three hours later (median T max2 about 4.5 hours post dosage)*, followed by a gradual decline (Figure 1). The means for C max and area under the curve (AUC) following a dosage of 20 mg of Methylphenidate HCl Extended-Release Capsules CD were slightly lower than those seen with 10 mg of the immediate-release methylphenidate, dosed at 0 and 4 hours. *25-30% of the patients had only one observed peak (C max ) concentration of methylphenidate. Figure 1: Methylphenidate Pharmacokinetics After Repeat Dosages of an Immediate Release (IR) Methylphenidate Product and Methylphenidate HCl Extended-Release Capsules CD in Pediatric Patients 7 to 12 Years of Age with ADHD Effect of Food: Ingestion of a high-fat meal with Methylphenidate HCl Extended-Release Capsules CD administration increased the mean C max and AUC of methylphenidate by about 30% and 17%, respectively. The presence of food delayed the early peak by approximately 1 hour (range -2 to 5 hours delay) [ see Dosage and Administration ( 2.1 )] . The bioavailability (C max and AUC) of methylphenidate was unaffected by sprinkling the Methylphenidate HCl Extended-Release Capsules CD extended-release capsule contents on applesauce as compared to the intact capsule. Distribution Plasma protein binding is 10% to 33%. The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate. Elimination The mean terminal half-life (t½) of methylphenidate following administration of Methylphenidate HCl Extended-Release Capsules CD (t½=6.8 hours) is longer than the mean terminal t½ following administration of methylphenidate hydrochloride immediate-release tablets (t½=2.9 hours) and methylphenidate hydrochloride extended-release tablets (t½=3.4 hours) in healthy adult volunteers. Metabolism: In vitro studies showed that methylphenidate was not metabolized by cytochrome P450 isoenzymes. Methylphenidate is metabolized primarily by deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity. Excretion: After oral administration of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was ritalinic acid, accounting for approximately 80% of the dosage. Specific Populations Male and Female Patients: The pharmacokinetics of methylphenidate after a single dosage of Methylphenidate HCl Extended-Release Capsules CD were similar between adult males and females. Patients with Renal Impairment: Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients with renal impairment. Since renal clearance is not an important route of methylphenidate clearance, and the major metabolite (ritalinic acid), has little or no pharmacologic activity, renal impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate after Methylphenidate HCl Extended-Release Capsules CD administration. Patients with Hepatic Impairment: Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients with hepatic impairment. Hepatic impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate because it is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body. Racial or Ethnic Groups: The influence of race on the pharmacokinetics of methylphenidate after Methylphenidate HCl Extended-Release Capsules CD administration has not been studied. Drug Interaction Studies Alcohol: An in vitro study was conducted to explore the effect of alcohol on the release characteristics of methylphenidate from the Methylphenidate HCl Extended-Release Capsules CD 60 mg extended-release capsules. At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released. The results with the 60 mg capsule are considered to be representative of the other strengths [see Drug Interactions ( 7 )] . In vitro studies showed that methylphenidate did not inhibit cytochrome P450 isoenzymes at clinically observed plasma drug concentrations. Figure 1"],"clinical_studies":["14 CLINICAL STUDIES Methylphenidate HCl Extended-Release Capsules CD was evaluated in a double-blind, parallel-group, placebo-controlled 3-week trial (Study 1) in which 321 untreated or previously treated pediatric patients 6 to 15 years of age with a DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD). Patients were required to have the combined or predominantly hyperactive-impulsive subtype of ADHD; patients with the predominantly inattentive subtype were excluded. Patients randomized to the Methylphenidate HCl Extended-Release Capsules CD group received 20 mg daily in the morning for the first week. Their Methylphenidate HCl Extended-Release Capsules CD dosage could be increased weekly to a maximum of 60 mg by the third week, depending on individual response to treatment. The patient’s regular school teacher completed the teachers’ version of the Conners’ Global Index Scale (TCGIS), a scale for assessing ADHD symptoms, in the morning and again in the afternoon on three alternate days of each treatment week. The primary efficacy endpoint was determined by the average of the total scores for the 10-item TCGIS completed by the classroom teacher in the morning and again in the afternoon on the three observation days during the last week of double-blind therapy. Patients in the Methylphenidate HCl Extended-Release Capsules CD group showed a statistically significant improvement in symptom scores from baseline over patients in the placebo group (See Figure 2 ). Separate analyses of TCGIS scores in the morning and afternoon revealed superiority in improvement in the Methylphenidate HCl Extended-Release Capsules CD group over the placebo group during both time periods (See Figure 3 ). Figure 2: Least Squares Mean Change from Baseline in TCGIS Total Score in Pediatric Patients 6 to 15 years of Age with ADHD (Study 1) Last observation carried forward analysis at week 3; Error bars represent the standard error of the mean. Figure 3 : Least Squares Mean Change from Baseline in TCGIS Total Score in Pediatric Patients 6 to 15 years of Age with ADHD in Study 1: Morning (AM) and Afternoon (PM) Last observation carried forward analysis at week 3; Error bars represent the standard error of the mean. F F"],"contraindications":["4 CONTRAINDICATIONS Methylphenidate HCl Extended-Release Capsules CD is contraindicated in patients: With known hypersensitivity reaction(s) to methylphenidate or other ingredients of Methylphenidate HCl Extended-Release Capsules CD. Angioedema has been reported in patients treated with Methylphenidate HCl Extended-Release Capsules CD. Anaphylactic reactions have been reported in patients treated with other methylphenidate products [see Adverse Reactions ( 6 )] . Taking a monoamine oxidase inhibitor (MAOI) or within 14 days of discontinuing use of an MAOI because of the risk of hypertensive crisis [see Drug Interactions ( 7 )] . With hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency because Methylphenidate HCl Extended-Release Capsules CD contains sucrose. With pheochromocytoma or a history of pheochromocytoma. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received a CNS stimulant. Methylphenidate HCl Extended-Release Capsules CD is contraindicated in patients ( 4 ): With known hypersensitivity reaction(s) to methylphenidate or ingredients in Methylphenidate HCl Extended-Release Capsules CD Taking a monoamine oxidase inhibitor (MAOI), or within 14 days of discontinuing a MAOI With hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency With pheochromocytoma or a history of pheochromocytoma"],"description":["11 DESCRIPTION Chemically, methylphenidate hydrochloride is d , l (racemic)- threo -methyl α-phenyl-2-piperidineacetate hydrochloride. Its empirical formula is C 14 H 19 NO 2 •HCl. Methylphenidate hydrochloride, USP is a white, odorless, crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77. Its structural formula is: Methylphenidate HCl Extended-Release Capsules CD (methylphenidate hydrochloride) extended-release capsules is a CNS stimulant. The extended-release capsules for oral administration comprise both immediate-release (IR) and extended-release (ER) beads such that 30% of the dosage is provided by the IR component and 70% of the dosage is provided by the ER component. Methylphenidate HCl Extended-Release Capsules CD is available in six extended-release capsule strengths containing: 10 mg of methylphenidate hydrochloride (3 mg IR; 7 mg ER) (equivalent to 10 mg of methylphenidate), 20 mg of methylphenidate hydrochloride (6 mg IR; 14 mg ER) (equivalent to 20 mg of methylphenidate), 30 mg of methylphenidate hydrochloride (9 mg IR; 21 mg ER) (equivalent to 30 mg of methylphenidate), 40 mg of methylphenidate hydrochloride (12 mg IR; 28 mg ER) (equivalent to 40 mg of methylphenidate), 50 mg of methylphenidate hydrochloride (15 mg IR; 35 mg ER) (equivalent to 50 mg of methylphenidate) 60 mg of methylphenidate hydrochloride (18 mg IR; 42 mg ER) (equivalent to 60 mg of methylphenidate). Methylphenidate HCl Extended-Release Capsules CD contains the following inactive ingredients: Dibutyl sebacate, ethylcellulose aqueous dispersion, gelatin, hydroxypropyl methylcellulose, polyethylene glycol, povidone, sugar spheres, and titanium dioxide. The extended-release capsules contain the following color agents: 10 mg: FD&C Blue No. 2, FDA/E172 Yellow Iron Oxide 20 mg: FD&C Blue No. 2 30 mg: FD&C Blue No. 2, FDA/E172 Red Iron Oxide 40 mg: FDA/E172 Yellow Iron Oxide 50 mg: FD&C Blue No. 2, FDA/E172 Red Iron Oxide formula"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Prior to initiating Methylphenidate HCl Extended-Release Capsules CD treatment, assess each patient’s risk for ( 2.1 ): Abuse, misuse, and addiction ( 5.1 ) Presence of cardiac disease ( 5.2 ) Developing a manic episode ( 5.4 ) A family history of tics or Tourette syndrome and clinically evaluate patients for motor or verbal tics or Tourette syndrome ( 5.10 ) Recommended starting dosage of Methylphenidate HCl Extended-Release Capsules CD in pediatric patients 6 to 15 years of age is 20 mg once daily.Dosage may be adjusted weekly in 10 mg to 20 mg increments to the maximum recommended dosage of 60 mg per day ( 2.2 ). Take orally once daily in the morning, before breakfast. Swallow the extended-release capsules whole with the aid of liquids.Alternatively, open the extended-release capsules and sprinkle the contents onto a small amount of applesauce (tablespoon) and give immediately and then drink fluids ( 2.3 ). Do not crush or chew the extended-release capsules ( 2.1 ) 2.1 Pretreatment Screening Prior to treating patients with Methylphenidate HCl Extended-Release Capsules CD, assess: The risk for abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 )] . For the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions ( 5.2 )] . The risk for developing a manic episode (e.g., history of depressive symptoms or a family history of suicide, bipolar disorder, or depression) [see Warnings and Precautions ( 5.4 )] . For a family history for tics or Tourette syndrome and clinically evaluate patients for motor or verbal tics or Tourette syndrome [see Warnings and Precautions ( 5.10 )] . 2.2 Recommended Dosage The recommended starting dosage of Methylphenidate HCl Extended-Release Capsules CD in pediatric patients 6 years of age and older is 20 mg once daily. Dosage may be adjusted weekly in 10 mg to 20 mg increments to the maximum recommended dosage of 60 mg per day. 2.3 Administration Instructions Take Methylphenidate HCl Extended-Release Capsules CD orally once daily in the morning, before breakfast [see Clinical Pharmacology ( 12.3 )]. Swallow the extended-release capsules whole with the aid of liquids. Alternatively, open the extended-release capsules and sprinkle the contents onto a small amount (tablespoon) of applesauce and administer immediately and then drink fluids. Do not store for future use. Do not crush or chew the extended-release capsules. 2.4 Dosage Reduction and Discontinuation If paradoxical aggravation of ADAD symptoms or Methylphenidate HCl Extended-Release Capsules CD-associated adverse reactions occur, reduce dosage or, if necessary, discontinue Methylphenidate HCl Extended-Release Capsules CD. If ADHD improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue Methylphenidate HCl Extended-Release Capsules CD."],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Methylphenidate HCl Extended-Release Capsules CD (methylphenidate hydrochloride) extended-release capsules are available in the following strengths (see Table 1 ): Table 1 : Strengths of Methylphenidate Hydrochloride and Identifying Characteristics of Methylphenidate HCl Extended-Release Capsules CD Strength Extended-Release Capsule Color (cap/body) Imprinting on Extended-Release Capsule Cap Imprinting on Extended- Release Capsule Body 10 mg green/white “LANNETT 4579” in white letters “10 mg” in black letters 20 mg blue/white “LANNETT 4580” in white letters “20 mg” in black letters 30 mg reddish-brown/white “LANNETT 4581” in white letters “30 mg” in black letters 40 mg yellow ivory/white “LANNETT 4582” in black letters “40 mg” in black letters 50 mg purple/white “LANNETT 4583” in white letters “50 mg” in black letters 60 mg white/white “LANNETT 4584” in black letters “60 mg” in black letters Extended-release capsules : 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg ( 3 )"],"dosage_forms_and_strengths_table":["<table> <col/> <col/> <col/> <col/> <tbody> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Strength</content> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Extended-Release</content> </paragraph> <paragraph> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Capsule Color</content> </paragraph> <paragraph> <content styleCode=\"bold\">(cap/body)</content> </paragraph> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Imprinting on </content> </paragraph> <paragraph> <content styleCode=\"bold\"> <content styleCode=\"bold\">Extended-Release </content> </content> </paragraph> <paragraph> <content styleCode=\"bold\"> <content styleCode=\"bold\"> </content> </content> <content styleCode=\"bold\">Capsule Cap</content> </paragraph> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Imprinting on</content> </paragraph> <paragraph> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Extended-</content> </paragraph> <paragraph> <content styleCode=\"bold\">Release </content> </paragraph> <paragraph> <content styleCode=\"bold\">Capsule Body</content> </paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">10 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">green/white  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4579&#x201D; in white letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;10 mg&#x201D; in black letters  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">20 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">blue/white</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4580&#x201D; in white letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;20 mg&#x201D; in black letters  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">30 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">reddish-brown/white  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4581&#x201D; in white letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;30 mg&#x201D; in black letters  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">40 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">yellow ivory/white  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4582&#x201D; in black letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;40 mg&#x201D; in black letters  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">50 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">purple/white  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4583&#x201D; in white letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;50 mg&#x201D; in black letters  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">60 mg</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">white/white   </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4584&#x201D; in black letters  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;60 mg&#x201D; in black letters  </td> </tr> </tbody> </table>"],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Methylphenidate HCl Extended-Release Capsules CD contains methylphenidate, a Schedule II controlled substance. 9.2 Abuse Methylphenidate HCl Extended-Release Capsules CD has a high potential for abuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions ( 5.1 )] . Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Methylphenidate HCl Extended-Release Capsules CD has a high potential for misuse. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Misuse, like abuse, is often associated with higher dosages and/or more frequent use of the drug, which may lead to adverse reactions similar to those seen in the context of abuse and substance use disorder. Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher dosages or unapproved methods of administration, such as snorting or injection. 9.3 Dependence Physical Dependence Methylphenidate HCl Extended-Release Capsules CD may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawal signs and symptoms after abrupt discontinuation or dosage reduction following prolonged use of CNS stimulants including Methylphenidate HCl Extended-Release Capsules CD include dysphoric mood; depression; fatigue; vivid; unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation. Tolerance Methylphenidate HCl Extended-Release Capsules CD may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dosage of a drug is required to produce the same effect that was once obtained at a lower dosage)."],"drug_interactions":["7 DRUG INTERACTIONS Table 3 describes clinically significant drug interactions with Methylphenidate HCl Extended-Release Capsules CD. Table 3: Clinically Significant Drug Interactions with Methylphenidate HCl Extended-Release Capsules CD Monoamine Oxidase Inhibitors Prevention or Management Concomitant use of Methylphenidate HCl Extended-Release Capsules CD with MAOIs or within 14 days after discontinuing an MAOI is contraindicated. Mechanism and Clinical Effect(s) Concomitant use of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD with MAOIs, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Antihypertensive Drugs Prevention or Management Increase monitoring for blood pressure and adjust the dosage of the antihypertensive drug, as needed. Mechanism and Clinical Effect(s) Methylphenidate HCl Extended-Release Capsules CD may decrease effectiveness of drugs used to treat hypertension [see Warnings and Precautions ( 5.3 )] . Halogenated Anesthetics Prevention or Management Avoid use of Methylphenidate HCl Extended-Release Capsules CD in patients being treated with anesthetics on the day of surgery. Mechanism and Clinical Effect(s) Concomitant use of Methylphenidate HCl Extended-Release Capsules CD with halogenated anesthetics may increase the risk of sudden blood pressure and heart rate increase during surgery. Risperidone Prevention or Management Monitor for signs of extrapyramidal symptoms. Mechanism and Clinical Effect(s) The risk of risperidone-associated extrapyramidal symptoms may increase in patients taking concomitant Methylphenidate HCl Extended-Release Capsules CD when there is a change in the Methylphenidate HCl Extended-Release Capsules CD or risperidone dosage. Alcohol Prevention or Management Avoid the use of alcohol while taking Methylphenidate HCl Extended-Release Capsules CD. Mechanism and Clinical Effect(s) Consumption of alcohol while taking Methylphenidate HCl Extended-Release Capsules CD resulted in a more rapid release of methylphenidate [see ClinicalPharmacology ( 12.3 ) ] which may increase Methylphenidate HCl Extended-Release Capsules CD-related adverse reactions and may reduce the effectiveness of Methylphenidate HCl Extended-Release Capsules CD during the later part of the dosing period due to lower methylphenidate exposure . Antihypertensive Drugs : Monitor blood pressure. Adjust dosage of antihypertensive drug as needed ( 7 ) See Full Prescribing Information, for additional clinically significant drug interactions. ( 7 )"],"drug_interactions_table":["<table> <col/> <col/> <tbody> <tr> <td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Monoamine Oxidase Inhibitors</content> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Prevention or  Management  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Concomitant use of Methylphenidate HCl Extended-Release Capsules CD with MAOIs or within 14 days after discontinuing an MAOI is contraindicated.</td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Mechanism and Clinical Effect(s)  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Concomitant use of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD with MAOIs, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.  </td> </tr> <tr> <td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Antihypertensive Drugs</content>   </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Prevention or  Management  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Increase monitoring for blood pressure and adjust the dosage of the antihypertensive drug, as needed.  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Mechanism and Clinical Effect(s)  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Methylphenidate HCl Extended-Release Capsules CD may decrease effectiveness of drugs used to treat hypertension <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#LINK_7699e091-fd5d-43fd-aa03-ddc77d12dea4\">5.3</linkHtml>)]</content>.  </td> </tr> <tr> <td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Halogenated Anesthetics</content>   </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Prevention or  Management  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Avoid use of Methylphenidate HCl Extended-Release Capsules CD in patients being treated with anesthetics on the day of surgery.  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Mechanism and Clinical Effect(s)  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph>Concomitant use of Methylphenidate HCl Extended-Release Capsules CD with halogenated anesthetics may increase the risk of sudden blood pressure and heart rate increase during surgery.</paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Risperidone</content>   </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Prevention or  Management</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Monitor for signs of extrapyramidal symptoms.  </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Mechanism and Clinical Effect(s)  </td> <td styleCode=\" Botrule Toprule Lrule Rrule\">The risk of risperidone-associated extrapyramidal symptoms may increase in patients taking concomitant Methylphenidate HCl Extended-Release Capsules CD when there is a change in the Methylphenidate HCl Extended-Release Capsules CD or risperidone dosage.  </td> </tr> <tr> <td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Alcohol</content> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Prevention or Management</td> <td styleCode=\" Botrule Toprule Lrule Rrule\"> Avoid the use of alcohol while taking Methylphenidate HCl Extended-Release Capsules CD. </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\">Mechanism and Clinical Effect(s)</td> <td styleCode=\" Botrule Toprule Lrule Rrule\">Consumption of alcohol while taking Methylphenidate HCl Extended-Release Capsules CD resulted in a more rapid release of methylphenidate <content styleCode=\"italics\">[see ClinicalPharmacology (</content> <content styleCode=\"italics\"> <content styleCode=\"underline\"> <linkHtml href=\"#LINK_60cdc50a-f929-400e-8f7e-a1402695cc88\">12.3</linkHtml> </content> </content> <content styleCode=\"italics\">)</content> <content styleCode=\"italics\">]</content> which may increase Methylphenidate HCl Extended-Release Capsules CD-related adverse reactions and may reduce the effectiveness of Methylphenidate HCl Extended-Release Capsules CD during the later part of the dosing period due to lower methylphenidate exposure<content styleCode=\"italics\">. </content> </td> </tr> </tbody> </table>"],"effective_time":"20261014","geriatric_use":["8.5 Geriatric Use Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients over the age of 65 years and is not indicated for use in adults."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Methylphenidate HCl Extended-Release Capsules CD (methylphenidate hydrochloride) extended-release capsules are available in six strengths (see Table 4 ): Table 4: Strength (methylphenidate hydrochloride), Identifying Characteristics, and Packaging Configurations of Methylphenidate HCl Extended-Release Capsules CD Strength Capsule Color (cap/body) Imprinting on Capsule Cap Imprinting on Capsule Body Capsules per Bottle NDC Number 10 mg green/white “LANNETT 4579” in white letters “10 mg” in black letters 100 NDC 0527-4579-37 20 mg blue/white “LANNETT 4580” in white letters “20 mg” in black letters 100 NDC 0527-4580-37 30 mg reddish-brown/white “LANNETT 4581” in white letters “30 mg” in black letters 100 NDC 0527-4581-37 40 mg yellow ivory/white “LANNETT 4582” in black letters “40 mg” in black letters 100 NDC 0527-4582-37 50 mg purple/white “LANNETT 4583” in white letters “50 mg” in black letters 100 NDC 0527-4583-37 60 mg white/white capsules “LANNETT 4584” in black letters “60 mg” in black letters 100 NDC 0527-4584-37 Storage and Handling Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]."],"how_supplied_table":["<table> <col/> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Strength</content> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Capsule Color </content> <content styleCode=\"bold\">(cap/body)</content> </paragraph> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Imprinting on Capsule Cap</content>   </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Imprinting on Capsule Body</content> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">Capsules per Bottle</content> </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <content styleCode=\"bold\">NDC Number</content> </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">10 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">green/white  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4579&#x201D; in white letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;10 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4579-37  </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">20 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">blue/white</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4580&#x201D; in white letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;20 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4580-37  </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">30 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">reddish-brown/white  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4581&#x201D; in white letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;30 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4581-37  </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">40 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">yellow ivory/white  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4582&#x201D; in black letters</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;40 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4582-37  </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">50 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">purple/white  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4583&#x201D; in white letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;50 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4583-37  </td> </tr> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">60 mg</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">white/white capsules</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;LANNETT 4584&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">&#x201C;60 mg&#x201D; in black letters  </td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">100</td> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\">NDC 0527-4584-37  </td> </tr> </tbody> </table>"],"id":"8e987008-a787-4cbd-8775-69e92239de2f","indications_and_usage":["1 INDICATIONS AND USAGE Methylphenidate HCl Extended-Release Capsules CD is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 years of age and older. Limitations of Use The use of Methylphenidate HCl Extended-Release Capsules CD is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g. weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )] . Methylphenidate HCl Extended-Release Capsules CD is a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 years of age and older. ( 1 ) Limitations of Use The use of Methylphenidate HCl Extended-Release Capsules CD is not recommended in pediatric patients younger than 6 years of age because they had higher exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. ( 5.7 , 8.4 )"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient and/or their caregivers to read the FDA-approved patient labeling ( Medication Guide ). Abuse, Misuse, and Addiction Educate patients and their families about the risks of abuse, misuse, and addiction of Methylphenidate HCl Extended-Release Capsules CD, which can lead to overdose and death, and proper disposal of any unused drug [see Warnings and Precautions ( 5.1 )], Drug Abuse and Dependence ( 9.2 ), Overdosage ( 10 )]. Advise them to store Methylphenidate HCl Extended-Release Capsules CD in a safe place, preferably locked, and instruct them to not give Methylphenidate HCl Extended-Release Capsules CD to anyone else. Risks to Patients with Serious Cardiac Disease Advise patients and/or their caregivers that there are potential risks to patients with serious cardiac disease, including sudden death, with Methylphenidate HCl Extended-Release Capsules CD use. Instruct them to contact a healthcare provider immediately if the patient develops symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see Warnings and Precautions ( 5.2 )]. Increased Blood Pressure and Heart Rate Instruct patients and their caregivers that Methylphenidate HCl Extended-Release Capsules CD can cause elevations of their blood pressure and heart rate [see Warnings and Precautions ( 5.3 )]. Psychiatric Adverse Reactions Advise patients and their caregivers that Methylphenidate HCl Extended-Release Capsules CD, at the recommended dosage, can cause psychotic or manic symptoms, even in patients without a prior history of psychotic symptoms or mania [see Warnings and Precautions ( 5.4 )]. Priapism Advise male patients and/or their caregivers of the possibility of priapism. Instruct them to seek immediate medical attention in the event of priapism [see Warnings and Precautions ( 5.5 )] . Peripheral Vasculopathy, Including Raynaud’s Phenomenon Instruct patients and/or their caregivers about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms; to report to their healthcare provider immediately with any signs of unexplained wounds appearing on fingers or toes while taking Methylphenidate HCl Extended-Release Capsules CD [see Warnings and Precautions ( 5.6 )] . Long-Term Suppression of Growth in Pediatric Patients Advise patients and/or their caregivers that Methylphenidate HCl Extended-Release Capsules CD may cause slowing of growth and weight loss in pediatric patients [see Warnings and Precautions ( 5.7 )]. Increased Intraocular Pressure and Glaucoma Advise patients and/or their caregivers what increased intraocular pressure and glaucoma may occur during Methylphenidate HCl Extended-Release Capsules CD treatment [see Warnings and Precautions ( 5.9 )] . Motor and Verbal Tics, and Worsening of Tourette Syndrome Advise patients and/or their caregivers that motor and verbal tics and worsening of Tourette syndrome may occur during Methylphenidate HCl Extended-Release Capsules CD treatment . Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette syndrome occurs [see Warnings and Precautions ( 5.10 )] . Alcohol Use Advise patients to avoid alcohol while taking Methylphenidate HCl Extended-Release Capsules CD. Consumption of alcohol while taking Methylphenidate HCl Extended-Release Capsules CD may result in a more rapid release of the dosage of methylphenidate [see Drug Interactions ( 7 )] . Pregnancy Registry Advise patients and/or their caregivers that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Methylphenidate HCl Extended-Release Capsules CD during pregnancy [see Use in Specific Populations ( 8.1 )]. Lactation Advise Methylphenidate HCl Extended-Release Capsules CD-treated breastfeeding women to monitor their infants for agitation, poor sleeping patterns, changes in feeding, and reduced weight gain [see Use in Specific Populations ( 8.2 )]. Administration Instructions Instruct patients and their caregivers that the Methylphenidate HCl Extended-Release Capsules CD extended-release capsules and the contents of the extended-release capsules must not be crushed or chewed. Instruct patients and their caregivers to either (1) swallow whole the extended-release capsules, or (2) alternatively, open the extended-release capsules and sprinkle the contents onto a small amount (tablespoon) of applesauce and take immediately and not to store for future use [see Dosage and Administration ( 2.3 )] . Distributed by: Lannett Company, Inc. Philadelphia, PA 19136 CIB72230C Rev. 10/2026"],"labor_and_delivery":["8.2 Lactation Risk Summary Limited published literature, based on milk sampling from a small number of methylphenidate-treated lactating women reports that methylphenidate is present in human milk, which resulted in infant dosages of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Methylphenidate HCl Extended-Release Capsules CD and any potential adverse effects on the breastfed infant from Methylphenidate HCl Extended-Release Capsules CD or from the underlying maternal condition. Clinical Considerations Monitor breastfeeding infants of Methylphenidate HCl Extended-Release Capsules CD-treated lactating women for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain."],"mechanism_of_action":["12.1 Mechanism of Action Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action of Methylphenidate HCl Extended-Release Capsules CD in the treatment of ADHD in pediatric patients 6 years of age and older is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dosage of approximately 60 mg/kg per day. This dosage is approximately 2 times the maximum recommended human dosage (MRHD) of 60 mg/day given to children on a mg/m 2 basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown. Methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dosage used was approximately 45 mg/kg/day, which is approximately 4 times the MRHD (children) on a mg/m 2 basis. In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dosage groups were exposed to 60 to 74 mg/kg per day of methylphenidate. Mutagenesis Methylphenidate was not mutagenic in the in vitro Ames reverse mutation assay, in the in vitro mouse lymphoma cell forward mutation assay, or in the in vitro chromosomal aberration assay using human lymphocytes. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary cells. Methylphenidate was negative in vivo in males and females in the mouse bone marrow micronucleus assay. Impairment of Fertility Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at dosages up to 160 mg/kg per day, approximately 10 times the maximum recommended human dosage of 60 mg/day given to adolescents on a mg/m 2 basis."],"openfda":{"application_number":["NDA021259"],"brand_name":["methylphenidate hydrochloride CD"],"generic_name":["METHYLPHENIDATE HYDROCHLORIDE"],"is_original_packager":[true],"manufacturer_name":["Lannett Company, LLC"],"package_ndc":["0527-4579-37","0527-4580-37","0527-4581-37","0527-4582-37","0527-4583-37","0527-4584-37"],"product_ndc":["0527-4579","0527-4580","0527-4581","0527-4582","0527-4583","0527-4584"],"product_type":["HUMAN PRESCRIPTION DRUG"],"route":["ORAL"],"rxcui":["1806181","1806187","1806189","1806191","1806193","1806197"],"spl_id":["8e987008-a787-4cbd-8775-69e92239de2f"],"spl_set_id":["e45c75dc-d381-475b-b649-a871c8a36e60"],"substance_name":["METHYLPHENIDATE HYDROCHLORIDE"],"unii":["4B3SC438HI"],"upc":["0305274579376","0305274580372","0305274582376","0305274584370"]},"overdosage":["10 OVERDOSAGE Clinical Effects of Overdose Overdose of CNS stimulants is characterized by the following sympathomimetic effects: Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop. CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur. Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop. Posterior reversible encephalopathy syndrome (PRES) symptoms including headache, altered mental status, hypertension, seizures, and visual disturbances including blindness have occurred in the setting of CNS stimulant overdose. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Diagnosis of PRES should be confirmed by radiological procedure (e.g., MRI). Overdose Management Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of Methylphenidate HCl Extended-Release Capsules CD should be considered when treating patients with overdose. Because methylphenidate has a large volume of distribution and is rapidly metabolized, dialysis is not useful. If an overdose of Methylphenidate HCl Extended-Release Capsules CD occurs, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 10 MG BOTTLE NDC 0527- 4579 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 10 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett 10 mg 100 count","PRINCIPAL DISPLAY PANEL - 20 MG BOTTLE NDC 0527- 4580 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 20 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett 20 mg 100 count","PRINCIPAL DISPLAY PANEL - 30 MG BOTTLE NDC 0527- 4581 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 30 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett label","PRINCIPAL DISPLAY PANEL - 40 MG BOTTLE NDC 0527- 4582 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 40 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett label","PRINCIPAL DISPLAY PANEL - 50 MG BOTTLE NDC 0527- 4583 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 50 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett 50 mg 100 count","PRINCIPAL DISPLAY PANEL - 60 MG BOTTLE NDC 0527- 4584 -37 Once Daily CII Methylphenidate HCl Extended-Release Capsules CD 60 mg A Medication Guide is required for every prescription dispensed. Please use accompanying Medication Guide. Rx Only 100 Capsules Lannett 60 mg 100 count"],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD for the treatment of ADHD have been established in pediatric patients 6 years of age and older. The safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD have not been established in pediatric patients below the age of 6 years. In studies evaluating extended-release methylphenidate products, patients 4 to <6 years of age had higher systemic methylphenidate exposures than those observed in older pediatric patients at the same dosage. Pediatric patients 4 to <6 years of age also had a higher incidence of adverse reactions, including weight loss. Therefore, the use of Methylphenidate HCl Extended-Release Capsules CD is not recommended in pediatric patients less than 6 years of age. Long-Term Suppression of Growth CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Growth (weight and height) should be monitored in pediatric patients during treatment with CNS stimulants, including Metadate CD. Pediatric patients who are not growing or gaining weight as expected may need to have their Methylphenidate HCl Extended-Release Capsules CD treatment interrupted [see Warnings and Precautions ( 5.6 )] . Juvenile Animal Toxicity Data In a study conducted in young rats, methylphenidate was administered orally at dosages of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 6 times the MRHD on a mg/m 2 basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dosage (12 times the MRHD on a mg/m 2 basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (half the MRHD on a mg/m 2 basis). The clinical significance of the long-term behavioral effects observed in rats is unknown."],"pharmacodynamics":["12.2 Pharmacodynamics Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD have not been fully characterized."],"pharmacokinetics":["12.3 Pharmacokinetics Following one week of 20 mg/day or 40 mg/day of Methylphenidate HCl Extended-Release Capsules CD to pediatric patients aged 7 to12 years old with ADHD, C max and AUC of methylphenidate were approximately proportional to the administered dosage. Absorption Following administration of Methylphenidate HCl Extended-Release Capsules CD in pediatric patients aged 7 to 12 years old with ADHD, the plasma concentration time profile of methylphenidate showed two phases of drug release with a sharp, initial slope similar to a methylphenidate immediate-release tablet (median T max1 about 1.5 hours post dosage), and a second rising portion approximately three hours later (median T max2 about 4.5 hours post dosage)*, followed by a gradual decline (Figure 1). The means for C max and area under the curve (AUC) following a dosage of 20 mg of Methylphenidate HCl Extended-Release Capsules CD were slightly lower than those seen with 10 mg of the immediate-release methylphenidate, dosed at 0 and 4 hours. *25-30% of the patients had only one observed peak (C max ) concentration of methylphenidate. Figure 1: Methylphenidate Pharmacokinetics After Repeat Dosages of an Immediate Release (IR) Methylphenidate Product and Methylphenidate HCl Extended-Release Capsules CD in Pediatric Patients 7 to 12 Years of Age with ADHD Effect of Food: Ingestion of a high-fat meal with Methylphenidate HCl Extended-Release Capsules CD administration increased the mean C max and AUC of methylphenidate by about 30% and 17%, respectively. The presence of food delayed the early peak by approximately 1 hour (range -2 to 5 hours delay) [ see Dosage and Administration ( 2.1 )] . The bioavailability (C max and AUC) of methylphenidate was unaffected by sprinkling the Methylphenidate HCl Extended-Release Capsules CD extended-release capsule contents on applesauce as compared to the intact capsule. Distribution Plasma protein binding is 10% to 33%. The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate. Elimination The mean terminal half-life (t½) of methylphenidate following administration of Methylphenidate HCl Extended-Release Capsules CD (t½=6.8 hours) is longer than the mean terminal t½ following administration of methylphenidate hydrochloride immediate-release tablets (t½=2.9 hours) and methylphenidate hydrochloride extended-release tablets (t½=3.4 hours) in healthy adult volunteers. Metabolism: In vitro studies showed that methylphenidate was not metabolized by cytochrome P450 isoenzymes. Methylphenidate is metabolized primarily by deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity. Excretion: After oral administration of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was ritalinic acid, accounting for approximately 80% of the dosage. Specific Populations Male and Female Patients: The pharmacokinetics of methylphenidate after a single dosage of Methylphenidate HCl Extended-Release Capsules CD were similar between adult males and females. Patients with Renal Impairment: Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients with renal impairment. Since renal clearance is not an important route of methylphenidate clearance, and the major metabolite (ritalinic acid), has little or no pharmacologic activity, renal impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate after Methylphenidate HCl Extended-Release Capsules CD administration. Patients with Hepatic Impairment: Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients with hepatic impairment. Hepatic impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate because it is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body. Racial or Ethnic Groups: The influence of race on the pharmacokinetics of methylphenidate after Methylphenidate HCl Extended-Release Capsules CD administration has not been studied. Drug Interaction Studies Alcohol: An in vitro study was conducted to explore the effect of alcohol on the release characteristics of methylphenidate from the Methylphenidate HCl Extended-Release Capsules CD 60 mg extended-release capsules. At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released. The results with the 60 mg capsule are considered to be representative of the other strengths [see Drug Interactions ( 7 )] . In vitro studies showed that methylphenidate did not inhibit cytochrome P450 isoenzymes at clinically observed plasma drug concentrations. Figure 1"],"pregnancy":["8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD drugs, including Methylphenidate HCl Extended-Release Capsules CD, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications . Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy have inconsistent findings about a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the fetus associated with the use of central nervous system (CNS) stimulants during pregnancy (see Clinical Considerations ) . No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at dosages up to 10 and 15 times, respectively, the maximum recommended human dosage (MRHD) of 60 mg/day given to adolescents on a mg/m 2 basis. However, spina bifida was observed in rabbits at a dosage 53 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre-and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at dosages 6 times the MRHD given to adolescents (see Data ) . The background risk of major birth defects and miscarriage in those with ADHD is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions: CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of a therapeutic dosage of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. Data Animal Data: In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at dosages of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dosage, which is approximately 52 times the MRHD of 60 mg/day given to adolescents on a mg/m 2 basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (15 times the MRHD given to adolescents on a mg/m 2 basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dosage level (10 times the MRHD of 60 mg/day given to adults on a mg/m 2 basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (3 times the MRHD on a mg/m 2 basis). When methylphenidate was administered to rats throughout pregnancy and lactation at dosages of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dosage (6 times the MRHD of 60 mg/day given to adults on a mg/m 2 basis), but no other effects on postnatal development were observed. The no effect level for pre-and postnatal development in rats was 15 mg/kg/day (~2 times the MRHD given to adolescents on a mg/m 2 basis)."],"recent_major_changes":["Contraindications ( 4 ) 07/2026"],"recent_major_changes_table":["<table width=\"449px\"> <col/> <col/> <tbody> <tr> <td>Contraindications (<linkHtml href=\"#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627\">4</linkHtml>)</td> <td> 07/2026</td> </tr> </tbody> </table>"],"set_id":"e45c75dc-d381-475b-b649-a871c8a36e60","spl_medguide":["MEDICATION GUIDE Methylphenidate Hydrochloride (meth” il fen’ i date hye” droe klor’ ide) Extended-Release Capsules CD for oral use, CII What is the most important information I should know about Methylphenidate HCl Extended-Release Capsules CD? Methylphenidate HCl Extended-Release Capsules CD may cause serious side effects, including: Abuse, misuse, and addiction. Methylphenidate HCl Extended-Release Capsules CD has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Methylphenidate HCl Extended-Release Capsules CD, other methylphenidate medicines, and amphetamine medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Methylphenidate HCl Extended-Release Capsules CD or when it is used in ways that are not approved, such as snorting or injection. Your healthcare provider should check your risk for abuse, misuse, and addiction before starting treatment with Methylphenidate HCl Extended-Release Capsules CD and will monitor you during treatment. Methylphenidate HCl Extended-Release Capsules CD may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider. Do not give Methylphenidate HCl Extended-Release Capsules CD to anyone else because it may cause death or harm them . Keep Methylphenidate HCl Extended-Release Capsules CD in a safe place and properly dispose of any unused medicine. See “ How should I store Methylphenidate HCl Extended-Release Capsules CD? ” for more information. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Risks for people with serious heart disease. Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you carefully for heart problems before starting Methylphenidate HCl Extended-Release Capsules CD. Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Methylphenidate HCl Extended-Release Capsules CD. Increased blood pressure and heart rate. Your healthcare provider should check your blood pressure and heart rate regularly during treatment with Methylphenidate HCl Extended-Release Capsules CD. Mental problems (psychiatric reactions), including: worsening behavior and thought problems in people with thought or psychotic disorders manic episodes in people with bipolar disorder new psychotic or manic symptoms in people without bipolar or psychotic disorders Tell your healthcare provider right away if any mental symptoms or problems develop or worsen during treatment with Methylphenidate HCl Extended-Release Capsules CD, including: greatly increased energy racing thoughts unusually grand ideas talking more or faster than usual severe trouble sleeping reckless behavior excessive happiness or irritability seeing or hearing things that are not real (hallucinations) See “ What are the possible side effects of Methylphenidate HCl Extended-Release Capsules CD? ” for more information about side effects. What is Methylphenidate HCl Extended-Release Capsules CD? Methylphenidate HCl Extended-Release Capsules CD is a central nervous system (CNS) stimulant prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years of age and older. Methylphenidate HCl Extended-Release Capsules CD may help increase attention and decrease impulsiveness and hyperactivity in children 6 years of age and older with ADHD. Methylphenidate HCl Extended-Release Capsules CD is not recommended for use in children under 6 years of age. Methylphenidate HCl Extended-Release Capsules CD is a federally controlled substance (CII) because it contains methylphenidate which can be abused and misused. Who should not take Methylphenidate HCl Extended-Release Capsules CD? Do not take Methylphenidate HCl Extended-Release Capsules CD if you: are allergic to methylphenidate hydrochloride or any of the ingredients in Methylphenidate HCl Extended-Release Capsules CD. See the end of this Medication Guide for a complete list of ingredients in Methylphenidate HCl Extended-Release Capsules CD. are taking or have stopped taking within the past 14 days a medicine called a monoamine oxidase inhibitor (MAOI). have an inherited problem with breaking down, absorbing, and processing certain types of sugar in the body. Methylphenidate HCl Extended-Release Capsules CD contains a type of sugar called sucrose. have a condition called pheochromocytoma or a history of pheochromocytoma. Before taking Methylphenidate HCl Extended-Release Capsules CD, tell your healthcare provider about all of your medical conditions, including if you: have heart problems, heart disease, heart defects, or high blood pressure, or have a family history of sudden death or heart problems have mental problems including psychosis, mania, bipolar illness, or depression or have a family history of suicide, bipolar illness, or depression have circulation problems in fingers or toes have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness) have or had repeated uncontrolled movements or sounds (tics) or Tourette syndrome, or have a family history of tics or Tourette syndrome plan to have surgery. You should not take Methylphenidate HCl Extended-Release Capsules CD on the day of your surgery if a certain type of anesthetic is used because it may increase your chance for a sudden increase in blood pressure and heart rate during surgery. are pregnant or plan to become pregnant. It is not known if Methylphenidate HCl Extended-Release Capsules CD will harm the unborn baby. There is a pregnancy exposure registry for women who are exposed to Methylphenidate HCl Extended-Release Capsules CD during pregnancy. The purpose of the registry is to collect information about the health of women exposed to Methylphenidate HCl Extended-Release Capsules CD and their baby. If you become pregnant during treatment with Methylphenidate HCl Extended-Release Capsules CD, talk to your healthcare provider about registering with the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visit online at https://womensmentalhealth.org/adhd-medications. are breastfeeding or plan to breastfeed. Methylphenidate HCl Extended-Release Capsules CD passes into breast milk. Talk to your healthcare provider about the best way to feed the baby during treatment with Methylphenidate HCl Extended-Release Capsules CD. If you breastfeed during treatment with Methylphenidate HCl Extended-Release Capsules CD, monitor your baby for agitation, poor sleeping patterns, changes in feeding, and reduced weight gain. Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Methylphenidate HCl Extended-Release Capsules CD and some medicines may interact with each other and cause serious side effects or affect the way Methylphenidate HCl Extended-Release Capsules CD or other medicines work. Sometimes the doses of other medicines will need to be changed during treatment with Methylphenidate HCl Extended-Release Capsules CD. Your healthcare provider will decide if Methylphenidate HCl Extended-Release Capsules CD can be taken with other medicines. Especially tell your healthcare provider if you take: other CNS stimulant medicines blood pressure medicines (anti-hypertensives) risperidone Know the medicines that you take. Keep a list of the medicines with you to show your healthcare provider and pharmacist when you get a new medicine. Do not start any new medicine during treatment with Methylphenidate HCl Extended-Release Capsules CD without talking to your healthcare provider first. How should I take Methylphenidate HCl Extended-Release Capsules CD? Take Methylphenidate HCl Extended-Release Capsules CD exactly as prescribed by your healthcare provider. Your healthcare provider may change the dose or stop treatment with Methylphenidate HCl Extended-Release Capsules CD if you get certain side effects. Take Methylphenidate HCl Extended-Release Capsules CD 1 time each day in the morning before breakfast. Swallow Methylphenidate HCl Extended-Release Capsules CD capsules whole with liquids. Do not crush or chew the capsules. If you cannot swallow the capsules whole: open the capsule and sprinkle all of the contents onto a tablespoonful of applesauce swallow all the applesauce and medicine mixture right away without chewing and then drink liquids do not store the applesauce and medicine mixture for later use If you take too much Methylphenidate HCl Extended-Release Capsules CD, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. What should I avoid while taking Methylphenidate HCl Extended-Release Capsules CD? Avoid drinking alcohol during treatment with Methylphenidate HCl Extended-Release Capsules CD. This can increase your risk for side effects and affect the way Methylphenidate HCl Extended-Release Capsules CD works. What are the possible side effects of Methylphenidate HCl Extended-Release Capsules CD? Methylphenidate HCl Extended-Release Capsules CD may cause serious side effects, including: See “ What is the most important information I should know about Methylphenidate HCl Extended-Release Capsules CD? ” Painful and prolonged erections (priapism). Priapism that may require surgery has happened in males who take medicines that contain methylphenidate. If you develop priapism, get medical help right away. Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Tell your healthcare provider if any of the following signs and symptoms of circulation problems develop during treatment: fingers or toes feel numb, cool, painful fingers or toes change color from pale, to blue, to red sensitivity to temperature in fingers or toes Call your healthcare provider right away if any unexplained wounds appear on the fingers or toes during treatment with Methylphenidate HCl Extended-Release Capsules CD. Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with Methylphenidate HCl Extended-Release Capsules CD. Methylphenidate HCl Extended-Release Capsules CD treatment may be stopped in children who are not growing or gaining weight as expected. Eye problems (increased pressure in the eye and glaucoma). Tell your healthcare provider right away if you develop changes in your vision or eye pain, swelling, or redness. New or worsening tics or worsening Tourette syndrome. Tell your healthcare provider if you get any new or worsening tics or worsening Tourette syndrome during treatment with Methylphenidate HCl Extended-Release Capsules CD. The most common side effects of Methylphenidate HCl Extended-Release Capsules CD, include headache, decreased appetite (anorexia), stomach (abdominal) pain, and trouble sleeping. These are not all of the possible side effects of Methylphenidate HCl Extended-Release Capsules CD. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Methylphenidate HCl Extended-Release Capsules CD? Store Methylphenidate HCl Extended-Release Capsules CD at room temperature between 68°F to 77°F (20°C to 25°C). Store Methylphenidate HCl Extended-Release Capsules CD in a safe place, like a locked cabinet. Dispose of remaining, unused, or expired Methylphenidate HCl Extended-Release Capsules CD by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix Methylphenidate HCl Extended-Release Capsules CD with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away Methylphenidate HCl Extended-Release Capsules CD in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines. Keep Methylphenidate HCl Extended-Release Capsules CD and all medicines out of the reach of children. General information about the safe and effective use of Methylphenidate HCl Extended-Release Capsules CD. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Methylphenidate HCl Extended-Release Capsules CD for a condition for which it was not prescribed. Do not give Methylphenidate HCl Extended-Release Capsules CD to other people, even if they have the same symptoms that you have. It may harm them and it is against the law. You can ask your pharmacist or healthcare provider for information about Methylphenidate HCl Extended-Release Capsules CD that is written for health professionals. What are the ingredients in Methylphenidate HCl Extended-Release Capsules CD? Active Ingredient: methylphenidate hydrochloride Inactive Ingredients: dibutyl sebacate, ethylcellulose aqueous dispersion, gelatin, hydroxypropyl methylcellulose, polyethylene glycol, povidone, sugar spheres, and titanium dioxide. The capsules also contain the following coloring agents: FD&C Blue No. 2 (10 mg, 20 mg, 30 mg, and 50 mg), FDA/E172 Yellow Iron Oxide (10 mg and 40 mg), and FDA/E172 Red Iron Oxide (30 mg and 50 mg). Distributed by: Lannett Company, Inc. Philadelphia, PA 19136 For more information about Methylphenidate HCl Extended-Release Capsules CD call 1-844-834-0530. This Medication Guide has been approved by the U.S. Food and Drug Administration. CIB72230C Revised: 10/2026"],"spl_medguide_table":["<table> <col/> <tbody> <tr> <td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">MEDICATION GUIDE</content> </paragraph> <paragraph> <content styleCode=\"bold\">Methylphenidate Hydrochloride</content> </paragraph> <paragraph> <content styleCode=\"bold\">(meth&#x201D; il fen&#x2019; i date hye&#x201D; droe klor&#x2019; ide)</content> </paragraph> <paragraph> <content styleCode=\"bold\">Extended-Release Capsules CD </content> </paragraph> <paragraph> <content styleCode=\"bold\"> <content styleCode=\"bold\">for oral use, CII</content> </content> </paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">What is the most important information I should know about Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Methylphenidate HCl Extended-Release Capsules CD may cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item> <content styleCode=\"bold\">Abuse, misuse, and addiction.</content> Methylphenidate HCl Extended-Release Capsules CD has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Methylphenidate HCl Extended-Release Capsules CD, other methylphenidate medicines, and amphetamine medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Methylphenidate HCl Extended-Release Capsules CD or when it is used in ways that are not approved, such as snorting or injection. <list listType=\"unordered\" styleCode=\"Circle\"> <item>Your healthcare provider should check your risk for abuse, misuse, and addiction before starting treatment with Methylphenidate HCl Extended-Release Capsules CD and will monitor you during treatment.</item> <item>Methylphenidate HCl Extended-Release Capsules CD may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item> <item> <content styleCode=\"bold\">Do not </content>give Methylphenidate HCl Extended-Release Capsules CD to anyone else <content styleCode=\"bold\">because it may cause death or harm them</content>.</item> <item> Keep Methylphenidate HCl Extended-Release Capsules CD in a safe place and properly dispose of any unused medicine. See &#x201C;<content styleCode=\"bold\">How should I store Methylphenidate HCl Extended-Release Capsules CD?</content>&#x201D; for more information.</item> <item>Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item> </list> </item> <item> <content styleCode=\"bold\">Risks for people with serious heart disease.</content> Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you carefully for heart problems before starting Methylphenidate HCl Extended-Release Capsules CD. Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Methylphenidate HCl Extended-Release Capsules CD.</item> <item> <content styleCode=\"bold\">Increased blood pressure and heart rate. </content>Your healthcare provider should check your blood pressure and heart rate regularly during treatment with Methylphenidate HCl Extended-Release Capsules CD.</item> <item> <content styleCode=\"bold\">Mental <content styleCode=\"bold\">problems (psychiatric reactions), including:</content> </content> <list listType=\"unordered\" styleCode=\"Circle\"> <item>worsening behavior and thought problems in people with thought or psychotic disorders</item> <item>manic episodes in people with bipolar disorder</item> <item>new psychotic or manic symptoms in people without bipolar or psychotic disorders</item> </list> </item> </list> <paragraph>Tell your healthcare provider right away if any mental symptoms or problems develop or worsen during treatment with Methylphenidate HCl Extended-Release Capsules CD, including:</paragraph> <list listType=\"unordered\" styleCode=\"Disk\"> <item>greatly increased energy</item> <item>racing thoughts</item> <item>unusually grand ideas</item> <item>talking more or faster than usual</item> <item>severe trouble sleeping</item> <item>reckless behavior</item> <item>excessive happiness or irritability</item> <item>seeing or hearing things that are not real (hallucinations)</item> </list> <paragraph>See <content styleCode=\"bold\"> <content styleCode=\"bold\">&#x201C;</content> <content styleCode=\"bold\">What are the possible side effects of Methylphenidate HCl Extended-Release Capsules CD?</content> <content styleCode=\"bold\">&#x201D; </content> </content>for more information about side effects.</paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">What is Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph>Methylphenidate HCl Extended-Release Capsules CD is a central nervous system (CNS) stimulant prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years of age and older. Methylphenidate HCl Extended-Release Capsules CD may help increase attention and decrease impulsiveness and hyperactivity in children 6 years of age and older with ADHD.</paragraph> <paragraph>Methylphenidate HCl Extended-Release Capsules CD is not recommended for use in children under 6 years of age.</paragraph> <paragraph> <content styleCode=\"bold\">Methylphenidate HCl Extended-Release Capsules CD is a federally controlled substance (CII) because it contains methylphenidate which can be abused and misused.</content> </paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Who should not take Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Do not take Methylphenidate HCl Extended-Release Capsules CD if you:</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>are allergic to methylphenidate hydrochloride or any of the ingredients in Methylphenidate HCl Extended-Release Capsules CD. See the end of this Medication Guide for a complete list of ingredients in Methylphenidate HCl Extended-Release Capsules CD.</item> <item>are taking or have stopped taking within the past 14 days a medicine called a monoamine oxidase inhibitor (MAOI).</item> <item>have an inherited problem with breaking down, absorbing, and processing certain types of sugar in the body. Methylphenidate HCl Extended-Release Capsules CD contains a type of sugar called sucrose.</item> <item>have a condition called pheochromocytoma or a history of pheochromocytoma.</item> </list> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">Before <content styleCode=\"bold\">taking Methylphenidate HCl Extended-Release Capsules CD, tell your healthcare provider about all of your medical conditions, including if you:</content> </content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>have heart problems, heart disease, heart defects, or high blood pressure, or have a family history of sudden death or heart problems</item> <item>have mental problems including psychosis, mania, bipolar illness, or depression or have a family history of suicide, bipolar illness, or depression</item> <item>have circulation problems in fingers or toes</item> <item>have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)</item> <item>have or had repeated uncontrolled movements or sounds (tics) or Tourette syndrome, or have a family history of tics or Tourette syndrome</item> <item> plan to have surgery. You should not take Methylphenidate HCl Extended-Release Capsules CD on the day of your surgery if a certain type of anesthetic is used because it may increase your chance for a sudden increase in blood pressure and heart rate during surgery.</item> <item>are pregnant or plan to become pregnant. It is not known if Methylphenidate HCl Extended-Release Capsules CD will harm the unborn baby. <list listType=\"unordered\" styleCode=\"Circle\"> <item>There is a pregnancy exposure registry for women who are exposed to Methylphenidate HCl Extended-Release Capsules CD during pregnancy. The purpose of the registry is to collect information about the health of women exposed to Methylphenidate HCl Extended-Release Capsules CD and their baby. If you become pregnant during treatment with Methylphenidate HCl Extended-Release Capsules CD, talk to your healthcare provider about registering with the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visit online at https://womensmentalhealth.org/adhd-medications.</item> </list> </item> <item>are breastfeeding or plan to breastfeed. Methylphenidate HCl Extended-Release Capsules CD passes into breast milk. Talk to your healthcare provider about the best way to feed the baby during treatment with Methylphenidate HCl Extended-Release Capsules CD. If you breastfeed during treatment with Methylphenidate HCl Extended-Release Capsules CD, monitor your baby for agitation, poor sleeping patterns, changes in feeding, and reduced weight gain.</item> </list> <paragraph> <content styleCode=\"bold\">Tell your healthcare provider about all the medicines that you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Methylphenidate HCl Extended-Release Capsules CD and some medicines may interact with each other and cause serious side effects or affect the way Methylphenidate HCl Extended-Release Capsules CD or other medicines work. Sometimes the doses of other medicines will need to be changed during treatment with Methylphenidate HCl Extended-Release Capsules CD. Your healthcare provider will decide if Methylphenidate HCl Extended-Release Capsules CD can be taken with other medicines.</paragraph> <paragraph> <content styleCode=\"bold\">Especially tell your healthcare provider if you take:</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>other CNS stimulant medicines</item> <item>blood pressure medicines (anti-hypertensives)</item> <item>risperidone</item> </list> <paragraph>Know the medicines that you take. Keep a list of the medicines with you to show your healthcare provider and pharmacist when you get a new medicine. <content styleCode=\"bold\"> <content styleCode=\"bold\">Do not start any new medicine during treatment with Methylphenidate HCl Extended-Release Capsules CD without talking to your healthcare provider first.</content> </content> </paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">How should I take Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>Take Methylphenidate HCl Extended-Release Capsules CD exactly as prescribed by your healthcare provider.</item> <item>Your healthcare provider may change the dose or stop treatment with Methylphenidate HCl Extended-Release Capsules CD if you get certain side effects. </item> <item>Take Methylphenidate HCl Extended-Release Capsules CD 1 time each day in the morning before breakfast.</item> <item>Swallow Methylphenidate HCl Extended-Release Capsules CD capsules whole with liquids.</item> <item> <content styleCode=\"bold\">Do not </content>crush or chew the capsules.</item> <item>If you cannot swallow the capsules whole: <list listType=\"unordered\" styleCode=\"Circle\"> <item>open the capsule and sprinkle all of the contents onto a tablespoonful of applesauce</item> <item>swallow all the applesauce and medicine mixture right away without chewing and then drink liquids</item> <item> <content styleCode=\"bold\">do not </content>store the applesauce and medicine mixture for later use</item> </list> </item> </list> <list listType=\"unordered\" styleCode=\"Disk\"> <item>If you take too much Methylphenidate HCl Extended-Release Capsules CD, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item> </list> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">What should I avoid while taking Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph>Avoid drinking alcohol during treatment with Methylphenidate HCl Extended-Release Capsules CD. This can increase your risk for side effects and affect the way Methylphenidate HCl Extended-Release Capsules CD works.</paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">What are the possible side effects of Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Methylphenidate HCl Extended-Release Capsules CD may cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>See &#x201C;<content styleCode=\"bold\">What is the most important information I should know about Methylphenidate HCl Extended-Release Capsules CD?</content>&#x201D;</item> <item> <content styleCode=\"bold\">Painful <content styleCode=\"bold\">and prolonged erections (priapism). </content> </content>Priapism that may require surgery has happened in males who take medicines that contain methylphenidate. If you develop priapism, get medical help right away.</item> <item> <content styleCode=\"bold\">Circulation <content styleCode=\"bold\">problems in fingers and toes (peripheral vasculopathy, including Raynaud&#x2019;s phenomenon).</content> </content> Tell your healthcare provider if any of the following signs and symptoms of circulation problems develop during treatment: <list listType=\"unordered\" styleCode=\"Circle\"> <item>fingers or toes feel numb, cool, painful</item> <item>fingers or toes change color from pale, to blue, to red</item> <item>sensitivity to temperature in fingers or toes</item> </list> </item> </list> <paragraph> <content styleCode=\"bold\">Call </content> <content styleCode=\"bold\">your healthcare provider right away if any unexplained wounds appear on the fingers or toes during treatment with Methylphenidate HCl Extended-Release Capsules CD.</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item> <content styleCode=\"bold\">Slowing <content styleCode=\"bold\">of growth (height and weight) in children. </content> </content>Children should have their height and weight checked often during treatment with Methylphenidate HCl Extended-Release Capsules CD. Methylphenidate HCl Extended-Release Capsules CD treatment may be stopped in children who are not growing or gaining weight as expected.</item> <item> <content styleCode=\"bold\">Eye problems (increased pressure in the eye and glaucoma).</content> Tell your healthcare provider right away if you develop changes in your vision or eye pain, swelling, or redness.</item> <item> <content styleCode=\"bold\">New or worsening tics or worsening Tourette syndrome.</content> Tell your healthcare provider if you get any new or worsening tics or worsening Tourette syndrome during treatment with Methylphenidate HCl Extended-Release Capsules CD.</item> </list> <paragraph> <content styleCode=\"bold\">The <content styleCode=\"bold\">most common side effects of Methylphenidate HCl Extended-Release Capsules CD, include </content> </content>headache, decreased appetite (anorexia), stomach (abdominal) pain, and trouble sleeping.</paragraph> <paragraph>These are not all of the possible side effects of Methylphenidate HCl Extended-Release Capsules CD.</paragraph> <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">How should I store Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <list listType=\"unordered\" styleCode=\"Disc\"> <item>Store Methylphenidate HCl Extended-Release Capsules CD at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item> <item>Store Methylphenidate HCl Extended-Release Capsules CD in a safe place, like a locked cabinet.</item> <item>Dispose of remaining, unused, or expired Methylphenidate HCl Extended-Release Capsules CD by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix Methylphenidate HCl Extended-Release Capsules CD with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away Methylphenidate HCl Extended-Release Capsules CD in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item> </list> <content styleCode=\"bold\">Keep Methylphenidate HCl Extended-Release Capsules CD and all medicines out of the reach of children.</content>   </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">General information about the safe and effective use of Methylphenidate HCl Extended-Release Capsules CD.</content> </paragraph> <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Methylphenidate HCl Extended-Release Capsules CD for a condition for which it was not prescribed. Do not give Methylphenidate HCl Extended-Release Capsules CD to other people, even if they have the same symptoms that you have. It may harm them and it is against the law. You can ask your pharmacist or healthcare provider for information about Methylphenidate HCl Extended-Release Capsules CD that is written for health professionals.</paragraph> </td> </tr> <tr> <td styleCode=\" Botrule Toprule Lrule Rrule\"> <paragraph> <content styleCode=\"bold\">What are the ingredients in Methylphenidate HCl Extended-Release Capsules CD?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Active Ingredient:</content> methylphenidate hydrochloride</paragraph> <paragraph> <content styleCode=\"bold\">Inactive Ingredients: </content>dibutyl sebacate, ethylcellulose aqueous dispersion, gelatin, hydroxypropyl methylcellulose, polyethylene glycol, povidone, sugar spheres, and titanium dioxide.</paragraph> <paragraph>The capsules also contain the following coloring agents: FD&amp;C Blue No. 2 (10 mg, 20 mg, 30 mg, and 50 mg), FDA/E172 Yellow Iron Oxide (10 mg and 40 mg), and FDA/E172 Red Iron Oxide (30 mg and 50 mg).</paragraph> <paragraph>Distributed by:  Lannett Company, Inc.  Philadelphia, PA 19136</paragraph> For more information about Methylphenidate HCl Extended-Release Capsules CD call 1-844-834-0530.  </td> </tr> </tbody> </table>"],"spl_product_data_elements":["methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE FD&C blue no. 2 FERRIC OXIDE YELLOW LANNETT;4579;10;mg methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE FD&C Blue No. 2 LANNETT;4580;20;mg methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE FD&C Blue No. 2 ferric oxide red reddish-brown LANNETT;4581;30;mg methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE ferric oxide yellow ivory LANNETT;4582;40;mg methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE FD&C blue no. 2 ferric oxide red LANNETT;4583;50;mg methylphenidate hydrochloride CD methylphenidate hydrochloride methylphenidate hydrochloride methylphenidate dibutyl sebacate ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A GELATIN HYDROXYPROPYL METHYLCELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED povidone, unspecified SUCROSE TITANIUM DIOXIDE LANNETT;4584;60;mg"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Monitor breastfeeding infants of Methylphenidate HCl Extended-Release Capsules CD-treated lactating women for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain ( 8.2 ). 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD drugs, including Methylphenidate HCl Extended-Release Capsules CD, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications . Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy have inconsistent findings about a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the fetus associated with the use of central nervous system (CNS) stimulants during pregnancy (see Clinical Considerations ) . No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at dosages up to 10 and 15 times, respectively, the maximum recommended human dosage (MRHD) of 60 mg/day given to adolescents on a mg/m 2 basis. However, spina bifida was observed in rabbits at a dosage 53 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre-and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at dosages 6 times the MRHD given to adolescents (see Data ) . The background risk of major birth defects and miscarriage in those with ADHD is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions: CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of a therapeutic dosage of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. Data Animal Data: In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at dosages of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dosage, which is approximately 52 times the MRHD of 60 mg/day given to adolescents on a mg/m 2 basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (15 times the MRHD given to adolescents on a mg/m 2 basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dosage level (10 times the MRHD of 60 mg/day given to adults on a mg/m 2 basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (3 times the MRHD on a mg/m 2 basis). When methylphenidate was administered to rats throughout pregnancy and lactation at dosages of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dosage (6 times the MRHD of 60 mg/day given to adults on a mg/m 2 basis), but no other effects on postnatal development were observed. The no effect level for pre-and postnatal development in rats was 15 mg/kg/day (~2 times the MRHD given to adolescents on a mg/m 2 basis). 8.2 Lactation Risk Summary Limited published literature, based on milk sampling from a small number of methylphenidate-treated lactating women reports that methylphenidate is present in human milk, which resulted in infant dosages of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Methylphenidate HCl Extended-Release Capsules CD and any potential adverse effects on the breastfed infant from Methylphenidate HCl Extended-Release Capsules CD or from the underlying maternal condition. Clinical Considerations Monitor breastfeeding infants of Methylphenidate HCl Extended-Release Capsules CD-treated lactating women for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. 8.4 Pediatric Use The safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD for the treatment of ADHD have been established in pediatric patients 6 years of age and older. The safety and effectiveness of Methylphenidate HCl Extended-Release Capsules CD have not been established in pediatric patients below the age of 6 years. In studies evaluating extended-release methylphenidate products, patients 4 to <6 years of age had higher systemic methylphenidate exposures than those observed in older pediatric patients at the same dosage. Pediatric patients 4 to <6 years of age also had a higher incidence of adverse reactions, including weight loss. Therefore, the use of Methylphenidate HCl Extended-Release Capsules CD is not recommended in pediatric patients less than 6 years of age. Long-Term Suppression of Growth CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Growth (weight and height) should be monitored in pediatric patients during treatment with CNS stimulants, including Metadate CD. Pediatric patients who are not growing or gaining weight as expected may need to have their Methylphenidate HCl Extended-Release Capsules CD treatment interrupted [see Warnings and Precautions ( 5.6 )] . Juvenile Animal Toxicity Data In a study conducted in young rats, methylphenidate was administered orally at dosages of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 6 times the MRHD on a mg/m 2 basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dosage (12 times the MRHD on a mg/m 2 basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (half the MRHD on a mg/m 2 basis). The clinical significance of the long-term behavioral effects observed in rats is unknown. 8.5 Geriatric Use Methylphenidate HCl Extended-Release Capsules CD has not been studied in patients over the age of 65 years and is not indicated for use in adults."],"version":"12","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Risks to Patients with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. ( 5.2 ) Increased Blood Pressure and Heart Rate : Monitor blood pressure and heart rate. ( 5.3 ) Psychiatric Adverse Reactions : If new psychotic or manic symptoms occur, consider discontinuing Methylphenidate HCl Extended-Release Capsules CD. ( 5.4 ) Priapism : If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. ( 5.5 ) Peripheral Vasculopathy, including Raynaud’s Phenomenon : Carefully assess for digital changes during Methylphenidate HCl Extended-Release Capsules CD treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. ( 5.6 ) Long-Term Suppression of Growth in Pediatric Patients : Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their Methylphenidate HCl Extended-Release Capsules CD treatment interrupted. ( 5.7 ) Acute Angle Closure Glaucoma : Methylphenidate HCl Extended-Release Capsules CD-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. ( 5.8 ) Increased Intraocular Pressure (IOP) and Glaucoma : Prescribe Methylphenidate HCl Extended-Release Capsules CD to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open angle glaucoma. ( 5.9 ) Motor and Verbal Tics, and Worsening of Tourette Syndrome : Regularly monitor patients for the emergence or worsening of tics or Tourette syndrome. Discontinue Methylphenidate HCl Extended-Release Capsules CD if clinically appropriate. ( 5.10 ) 5.1 Abuse, Misuse, and Addiction Methylphenidate HCl Extended-Release Capsules CD has a high potential for abuse and misuse. The use of Methylphenidate HCl Extended-Release Capsules CD exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing Methylphenidate HCl Extended-Release Capsules CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients and/or their caregivers to store Methylphenidate HCl Extended-Release Capsules CD in a safe place, preferably locked, and instruct patients and/or their caregivers to not give Methylphenidate HCl Extended-Release Capsules CD to anyone else. Throughout Methylphenidate HCl Extended-Release Capsules CD treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. 5.2 Risks to Patients with Serious Cardiac Disease Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended dosage. Prior to treating patients with Methylphenidate HCl Extended-Release Capsules CD, assess for the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). Avoid Methylphenidate HCl Extended-Release Capsules CD use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac problems. 5.3 Increased Blood Pressure and Heart Rate CNS stimulants cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Some patients may have larger increases. Monitor all Methylphenidate HCl Extended-Release Capsules CD treated patients for hypertension and tachycardia. 5.4 Psychiatric Adverse Reactions Exacerbation of Pre-Existing Psychosis in Patients with a Psychotic Disorde r CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating Methylphenidate HCl Extended-Release Capsules CD treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression). New Psychotic or Manic Symptoms in Patients without a History of a Bipolar or Psychotic Disorder CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, at the recommended dosages, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNC stimulant-treated patients, compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing Methylphenidate HCl Extended-Release Capsules CD. 5.5 Priapism Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patients. Although priapism was not reported with methylphenidate initiation, it developed after some time on methylphenidate, often subsequent to an increase in dosage. Priapism also occurred during methylphenidate withdrawal (drug holidays or during discontinuation). Methylphenidate HCl Extended-Release Capsules CD-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention. 5.6 Peripheral Vasculopathy, Including Raynaud’s Phenomenon CNS stimulants, including Methylphenidate HCl Extended-Release Capsules CD, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms of these cases of peripheral vasculopathy were usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction in or discontinuation of the CNS stimulant. Carefully assess for digital changes during Methylphenidate HCl Extended-Release Capsules CD treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for Methylphenidate HCl Extended-Release Capsules CD-treated patients who develop signs of symptoms of peripheral vasculopathy. 5.7 Long-Term Suppression of Growth in Pediatric Patients CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate treatment for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period. Methylphenidate HCl Extended-Release Capsules CD is not approved for use and is not recommended in pediatric patients below 6 years of age because of a higher incidence of adverse reactions including weight loss [see Use in Specific Populations ( 8.4 )] . Closely monitor growth (weight and height) in Methylphenidate HCl Extended-Release Capsules CD-treated pediatric patients. Pediatric patients who are not growing or gaining height or weight as expected may need to have their Methylphenidate HCl Extended-Release Capsules CD treatment interrupted. 5.8 Acute Angle Closure Glaucoma There have been reports of angle closure glaucoma associated with methylphenidate treatment. Although the mechanism is not clear, Methylphenidate HCl Extended-Release Capsules CD-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. 5.9 Increased Intraocular Pressure and Glaucoma There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment [see Adverse Reactions ( 6.2 )] . Prescribe Methylphenidate HCl Extended-Release Capsules CD to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor Methylphenidate HCl Extended-Release Capsules CD-treated patients with a history of abnormally increased IOP or open angle glaucoma. 5.10 Motor and Verbal Tics, and Worsening of Tourette Syndrome CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette syndrome has also been reported [see Adverse Reactions ( 6.2 )] . Before initiating Methylphenidate HCl Extended-Release Capsules CD, assess the family history for tics or Tourette syndrome and clinically evaluate patients for tics or Tourette syndrome. Regularly monitor Methylphenidate HCl Extended-Release Capsules CD-treated patients for the emergence or worsening of tics or Tourette syndrome, and discontinue Methylphenidate HCl Extended-Release Capsules CD if clinically appropriate."]}